Evaluation of the Effect of Morphine and Imiquimodon Expression of TLR2 and TLR4 from Lesion RNA Extracted from BALB/c Mice Infected with Leishmania major

Parisa Ebrahimisadr 1, Fatemeh Ghaffarifar 1*, John Horton 2, Abdolhossein Dalimi 1, and Zohreh Sharifi 3

1. Department of Parasitology and Entomology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
2. Tropical Projects, Hitchin, United Kingdom
3. Blood Transfusion Research Center, High Institute for Education and Research in Transfusion Medicine, Tehran, Iran

Abstract

Background: Toll-Like Receptors (TLRs) are the cause of phagocytosis activation and destruction of the infection agents. In addition, new evidences support the idea that TLRs play a vital role in starting the acquired immunity reactions.

Methods: In this study, it has been attempted to infect the BALB/c mice with Leishmania major (L. major) and treat them using morphine and imiquimod; then the expressions of TLR2,4 from treated lesion were studied by using Real-Time PCR method. Treatment with morphine 1 mg/kg, imiquimod 5% and nalmefene 1 mg/kg began four weeks after the challenge. After treatment period, half of the mice of each group were killed and their lesions were isolated for RNA extraction and making cDNA. For the rest of mice, lesion size was measured weekly.

Results: The results showed increase of expression of TLR2 gene among all treated groups relative to the control, and the difference was significant (p<0.05). The expression of TLR4 gene only was reduced in groups under treatment with morphine and morphine plus nalmefene relative to the control group and in the other groups increased. The highest expression of TLR2 was seen in the group treated by glucantime (p<0.0001).

Conclusion: However, in this study it was found that despite decreasing the size of lesion in all treated groups, expression of TLR4 in the morphine, nalmefene, morphine plus nalmefene treated groups compared to the control group was decreased. Therefore, morphine may have a different function mechanism in treatment of the Leishmaniasis with the L. major.

Keywords: Leishmania major, Lesions, Mice, Morphine, Toll-like receptors

Introduction

Leishmaniasis is a complex disease caused by various species of Leishmania, with a variety of clinical features 1. Innate immunity system is capable of detecting the protected microbial structures or microbial metabolism products ([Pathogen Associated Molecular Patterns (PAMPs)], through a set of encoded receptors, called Pattern Reception Recognition (PRR) model 2. PRRs of the innate immunity system, specifically Toll-Like Receptors (TLRs) are responsible for the acute inflammatory responses, through induction of anti-microbial genes and inflammatory cytokines. TLRs play a crucial role in innate and acquired immunity systems as well as increase of phagocytosis and parasite killing process 3. Imiquimod components stimulate the innate immunity systems directly and lead to production of cytokines 4. Morphine function is caused by opioid receptor's intermediates 5. The first is a selective drug for the treatment of Leishmaniasis of antimony compounds. However, these drugs also have side effects such as drug resistance and relapse after treatment 6. Nalmefene is an antagonist of opioid and acts as an inhibitor for opioid receptors and could increase intra-cellular pathogenicity 7. There are a few studies on TLR2 and TLR4 in animal model and the probable relation with Leishmania infections 8. In this study, it has been attempted to infect the BALB/c mice with Leishmania major (L. major) and treat them using morphine and imiquimod; then the expression levels of TLRs 2 and TLR4 were evaluated in treated lesions.
Materials and Methods

The *L. major* strain (MRHO/IR/75/ER) was stored in Parasitology Department, Faculty of Medical Sciences, Tarbiat Modares University. Promastigotes of the *L. major* were cultured in RPMI 1640 (Gibco, US) media contained FBS 10% (Fetal Bovine Serum, Gibco, US) with 100 IU/ml penicillin and 100 µg/ml streptomycin in 24-26°C incubator. Female BALB/c mice (6-8 weeks) were purchased from Pasteur Institute of Iran. The BALB/c mice were kept under standard light, food and water conditions. When the parasite entered the stationary phase, 2x10⁶ promastigotes were injected to the tail base of BALB/c mice ³. Treatment was started after inoculation and continued for four weeks. Next, 1 mg/kg morphine sulfate was used once a week (Temad Co.). Imiquimod (5% Aldara cream, MEDA Co.) and nalmefene (Selinco Co.) were prepared according to the instruction of the producer. Glucantime (Sanofi-Aventis, France) was applied as the positive control. After ulceration, ten BALB/c mice from each group were treated by various drugs for 4 weeks according to the following classification:

1. Control (Untreated mice); 2. Treated with morphine (1 mg/kg, once a week for 4 weeks after the injury), subcutaneous injection (M); 3. Treated with nalmefene (1 mg/kg, once a week for four weeks, intraperitoneal injection) (N); 4. Treated with glucantime (20 mg/kg daily for 28 days, intramuscular injection) (G); 5. Treated with imiquimod (5% imiquimod cream, Aldara, topical treatment) (I); 6. Treated with nalmefene and morphine (N+M); 7. Treated with nalmefene and glucantime (N+G); 8. Treated with imiquimod and morphine (I+M) and 9. Treated with imiquimod and glucantime (I+G).

After treatment period, half of the mice of each group were killed and their lesion was isolated in plates; they were homogenized, and RNA was extracted according to Qiaqen Kit protocol (RNeasy Mini Kit, Qiaqen Company).

The amount of the extracted RNA was measured using Biophotometer device. Next, 1 µg of the RNA was used to make cDNA according to the Qiaqen Kit protocol (Quanti Tect Reverse Transcription Kit, Qiaqen company). In this study, the QIAGEN Master cycler was used to test the real-time PCR quality. For analysis of expression of TLR2 and TLR4, in a total volume of 25 µl (2 µl cDNA sample, 1 µl of each primer, 12.5 µl of SYBR Green PCR Master Mix and 8.5 µl of injected distilled water was used. GAPDH was used as an internal control. The quantitative real-time PCR conditions were as follows: 95°C for 15 min (95°C for 15 s, 60°C for 30 s, 72°C for 30 s) for 40 cycles. Relative TLR2 and TLR4 expressions were normalized by GAPDH and fold changes were calculated using 2^(-ΔΔCt) method.

The sequences of these primers are as follows:

TLR2, F: 5’-ACCTGGGTGTTTACACGTC-3’
TLR2, R: 5’-CGATGGAATCGATGATGTTG-3’

TLR4, F: 5’-ACCTGGGTGTTTACACGTC-3’
TLR4, R: 5’-ACCTGGGTGTTTACACGTC-3’
GAPDH, F: 5’-ATGGACTGTGTCATGAGCC-3’
GAPDH, R: 5’-ATTGTGCAATGTCATCTTG-3’

Lesion measurement

Lesion size was measured weekly in the rest of mice in each group. Measurement was conducted using caliper ruler for 7 weeks.

Statistical analysis

Real time PCR was performed in triplicates. The results were calculated as mean±SD. To compare values, p-values of <0.05 were considered significant. All analysis was performed using Graph Pad Prism (Version 5) and online site (Pcr data analysis. sabiosciences.com). At first, Kolmogorov-Smirnov test was done and after normal distribution for our data, one way ANOVA was conducted.

Results

The results were normalized based on the internal control gene of GAPDH. They show that increase of expression of TLR2 gene relative to the control group is apparent among all groups, and the difference was significant (p<0.05). The highest level of expression of TLR2 was seen in the groups treated by glucantime, imiquimod and imiquimod plus morphine, respectively. The expression of TLR4 gene was reduced in groups under treatment with morphine and morphine plus nalmefene relative to the control group. The difference was meaningful in all groups, except in imiquimod plus glucantime group, despite expression increase. The highest expression was seen in the group treated by glucantime (p=0.00 11; mean=14.682) followed by the groups treated by imiquimod and imiquimod plus morphine, (p=0.0022, p=0.0073) respectively (Figure 1). The expression of TLR2 and TLR4 in morphine and glucantime groups in comparison with control group showed significant difference (p<0.01).

![Figure 1](https://example.com/figure1.png)

Figure 1. Mean and SD of expression of TLR2 (A) and TLR4 (B) as a relative fold change by real time PCR in lesions of infected mice compared to control by using ΔΔCt method normalized with GAPDH Control (Infected mice), M (1 mg/kg morphine), N (1 mg/kg nalmefene), G (20 mg/kg glucantime), I (Cream 5% imiquimod), M+N (1 mg/kg morphine+1 mg/kg nalmefene), N+G (1 mg/kg nalmefene+20 mg/kg glucantime), I+M (Cream 5% imiquimod+1 mg/kg morphine) *(p<0.05), **(p<0.01).
Expression of TLR2 and TLR4 from Lesions of the BALB/c Mice

<table>
<thead>
<tr>
<th>Group</th>
<th>Control</th>
<th>M</th>
<th>N</th>
<th>G</th>
<th>I</th>
<th>N+M</th>
<th>N+G</th>
<th>I+M</th>
<th>I+G</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean±SD</td>
<td>Mean±SD</td>
<td>Mean±SD</td>
<td>Mean±SD</td>
<td>Mean±SD</td>
<td>Mean±SD</td>
<td>Mean±SD</td>
<td>Mean±SD</td>
<td>Mean±SD</td>
<td>Mean±SD</td>
</tr>
<tr>
<td>4</td>
<td>7.46±0.61</td>
<td>6.92±0.68</td>
<td>6.72±0.76</td>
<td>6.68±1.08</td>
<td>7.12±1.01</td>
<td>6.74±0.84</td>
<td>7±0.78</td>
<td>6.76±0.68</td>
<td>6.28±0.77</td>
</tr>
<tr>
<td>5</td>
<td>8.88±0.63</td>
<td>5.78±0.71</td>
<td>5.88±0.68</td>
<td>5.11±0.87</td>
<td>5.74±0.95</td>
<td>5.86±0.96</td>
<td>5.32±0.81</td>
<td>5.26±0.74</td>
<td>5.19±0.64</td>
</tr>
<tr>
<td>6</td>
<td>9.41±0.86</td>
<td>4.93±0.56</td>
<td>5.02±0.87</td>
<td>4.28±1.01</td>
<td>4.61±0.76</td>
<td>4.81±0.63</td>
<td>4.12±0.91</td>
<td>3.96±0.64</td>
<td>3.85±0.83</td>
</tr>
<tr>
<td>7</td>
<td>10.4±0.72</td>
<td>3.71±0.75</td>
<td>3.25±0.74</td>
<td>3.05±0.98</td>
<td>3.02±0.82</td>
<td>3.22±0.86</td>
<td>3.05±0.97</td>
<td>2.84±0.73</td>
<td>2.96±0.69</td>
</tr>
</tbody>
</table>

The mean lesion size decreased in all treated groups and the differences with control group were significant (p<0.05). However, in this study, it was found that despite decreasing the size of lesion in all treatment groups, expression of TLR4 in the morphine, nalmefene, morphine plus nalmefene treated groups compared to the control group was decreased. In all of the groups, the reduction in lesion size was observed in the control group. The mean lesion size in the control groups was 7.46 mm after challenge; at the end of week 7, the mice lesion size reached 10.4 mm. All treated groups showed a significant difference in comparison with the control group after 6 weeks (p<0.05, Table 1, Chart 1).

**Discussion**

Macrophages are necessary for the Leishmaniasis survival, reproduction and differentiation. Immune systems are suppressed by drug addiction so the host will be sensitive to infectious disease. Concerning the TLRs signaling, immunity response with intermediate has important TLR4 in clinical systems. Inhibition of TLR2, all groups treated by various drugs had increased expression, relative to the control group. Toluei et al. also found similar results in human lesions. The highest level of expression belongs to the glucantime treated group (p<0.0001). Other groups had also meaningful difference with the control group (p<0.001), except for the imiquimod plus glucantime treated group (p=0.0133). TLR4 has a controlling role in infection with Leishmania major whose increase of expression reduces the lesion. The results show that TLR2 increases expression in all groups compared with the control group and the difference between them is significant.

**Conclusion**

Therefore, morphine may have a different function mechanism in treatment of the infection with the L. major. Morphine increases the expression of TLR2 and decreases TLR4 whereas imiquimod increases the expression of both TLR2 and TLR4. The results of combination of morphine plus imiquimod were similar to imiquimod alone. At the end, it is suggested that the expression of other TLRs also be evaluated in the mice's lesion.

**Acknowledgement**

This work supported by Tarbiat Modares University. The authors would like to thank Professor Marcel Hommel for providing J774 cell line.

**Ethical Statement**

This study was approved in Medical Ethics Committee on 2016-Feb-09, with issue number 52/D/8207.

**References**


